The Asia Pacific Neurostimulation Devices Market would witness market growth of 13.9% CAGR during the forecast period (2020-2026).
Increased mental health awareness and the prevalence of neurological diseases along with numerous initiatives taken up by the government and private entities have been contributing to the exponential market growth. Factors such as improved healthcare infrastructure, an increasing number of healthcare reforms, and extensive healthcare spending in emerging markets such as India and China to overcome unmet medical needs in these regions are boosting demand for neurostimulators.
The rapid rise of COVID-19 infections leads to an increased concern for the shortage of essential life-saving devices and other vital health care to prevent the spread of this pandemic and provide the infected with optimum care. Additionally, for COVID-19 patients, who may require critical care, ventilators act as a vital treatment preference until a pharmacological treatment is developed. In addition, a wide variety of test-kits (antibody samples, self-administered, and others) require a rapid acceleration in the manufacturing process.
In conjunction with the available limited treatment options for the disease, the high product efficiency in the treatment of epilepsy is expected to boost market growth throughout the forecast period. Essential tremor is characterized by severe unintentional limb movement. The condition has an impact on the neck, jaw, and other parts of the body. The rising global population of geriatric diseases is among the most significant causes of tremor. Rising depression cases are also likely to contribute to the market development as neurostimulation equipment can easily handle electrical brain signals by activating or inhibiting them.
Based on Devices, the market is segmented into Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators and Other Devices. Based on Applications, the market is segmented into Pain Management, Hearing Loss, Urinary Incontinence, Parkinson’s Disease, Epilepsy and Other Applications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Nevro Corporation, Medtronic PLC, NeuroSigma, Inc., Integer Holdings Corporation, LivaNova PLC, NeuroPace, Inc., Neuronetics, Inc., and Synapse BioMedical, Inc.
Scope of the Study
• Spinal Cord Stimulators
• Deep Brain Stimulators
• Sacral Nerve Stimulators
• Vagus Nerve Stimulators and
• Other Devices
• Pain Management
• Hearing Loss
• Urinary Incontinence
• Parkinson’s Disease
• Epilepsy and
• Other Applications
• South Korea
• Rest of Asia Pacific
• Abbott Laboratories
• Boston Scientific Corporation
• Nevro Corporation
• Medtronic PLC
• NeuroSigma, Inc.
• Integer Holdings Corporation
• LivaNova PLC
• NeuroPace, Inc.
• Neuronetics, Inc.
• Synapse BioMedical, Inc.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
Premenstrual Syndrome Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Premenstrual Syndrome Global Clinical Trials Review, H1, 2020" provides an overview of Premenstrual Syndrome Clinical trials scenario.This report provides top line data relating to the clinical trials...
‘Treatment-resistant depression (TRD)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Treatment-resistant depression, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Treatment-resistant depression (TRD) Disease Understanding Treatment-resistant...
Multiple Sclerosis Therapies Market by Type (Immunosuppressants and Immunomodulators) and Route of Administration (Oral, Injectable, and Intravenous): Global Opportunity Analysis and Industry Forecast, 2019–2026 The global multiple sclerosis therapies market was valued at $22.99 million in 2018, and is projected to...
174 pages •
By Global Industry Analysts
• Jul 2020
Global Deep Brain Stimulation Devices Market to Reach $2.1 Billion by 2027 Amid the COVID-19 crisis, the global market for Deep Brain Stimulation Devices estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$2.1 Billion by 2027, growing at a CAGR of 10.1% over the analysis period 2020-2027. Parkinson’s,...
Neurostimulation Devices Market by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others) Application (Pain Management, Hearing Loss, Urinary Incontinence, Parkinson’s Disease, Epilepsy, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026 The...
The global neurostimulation devices market reached a value of US$ 5.5 Billion in 2019. A neurostimulation device is a programmable medical transmitter that can deliver electrical signals to the specific parts of the human brain. It is also used to stimulate, inhibit, modify, regulate and alter the activity of the autonomous, central and peripheral...
‘Postpartum Depression (PPD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Postpartum Depression (PPD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Postpartum Depression (PPD) Understanding Postpartum...
5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2020 Summary 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins...
Metabotropic Glutamate Receptor 1 - Pipeline Review, H1 2020 Summary Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) pipeline Target constitutes close to 5 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest...
Depression - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2020, provides an overview of the Depression (Central Nervous System) pipeline landscape. Depression is a mood disorder that causes a persistent feeling...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.